

**WILLIAM R. SHORT, MD, MPH**Division of Infectious Diseases,  
Jefferson Medical College of Thomas  
Jefferson University, Philadelphia, PA**JEAN R. ANDERSON, MD**The Johns Hopkins School of Medicine,  
Baltimore, MD

# Caring for women with HIV: Unique needs and challenges

## ABSTRACT

Women infected with human immunodeficiency virus (HIV) have unique needs. Treatment recommendations are the same for men and women, but in women, fertility desires, pregnancy, contraception, and aging must be taken into account in their medical care.

## KEY POINTS

The number of women living with HIV has increased over the past 30 years, and African American women bear a disproportionate burden of disease.

Women of all ages are at risk of acquiring HIV; therefore, HIV testing should be part of routine care.

Preconception counseling is an essential component of both primary and preventive care and should be the standard of care for all women of reproductive age with HIV.

Women with HIV have the same gynecologic problems as all women but may be more vulnerable to certain conditions, such as human papillomavirus infection.

**M**ORE THAN 30 years into the human immunodeficiency virus (HIV) epidemic, our understanding of the needs of women living with this virus continues to evolve. In the early years of the epidemic, managing HIV was all about preventing death and treating opportunistic infections. But now it is also about enabling patients to live long, healthy, and productive lives and preventing new HIV infections. In women, these goals can only be achieved by paying careful attention to sex-specific issues.

*See related editorial, page 702*

As a result of longer survival, HIV-infected persons are increasingly developing common health problems that also affect the general population and that require screening, management, and monitoring by primary care providers. Because people infected with HIV are typically seen by both an HIV specialist and a primary care provider, HIV specialists need to be familiar with primary care issues and primary care providers need to be familiar with HIV care recommendations in order to provide optimal care.

## ■ AFRICAN AMERICAN WOMEN BEAR A DISPROPORTIONATE BURDEN

In the United States, HIV was first reported in women in 1983 among those who had been steady sexual partners of males with acquired immune deficiency syndrome.<sup>1</sup> Although men with HIV still outnumber women, the number of women with HIV has increased rapidly. At the end of 2010 an estimated one in four people with HIV in the United States was female.<sup>2</sup>

**TABLE 1**

**Estimates of new HIV infections in the United States by subgroup, 2010**

White MSM	11,200
Black MSM	10,600
Hispanic MSM	6,700
Black heterosexual women	5,300
Black heterosexual men	2,700
White heterosexual women	1,300
Hispanic heterosexual women	1,200
Black male intravenous drug users	1,100
Black female intravenous drug users	850
Hispanic heterosexual men	780

HIV = human immunodeficiency virus; MSM = men who have sex with men

CENTERS FOR DISEASE CONTROL AND PREVENTION.  
HIV IN THE UNITED STATES: AT A GLANCE.  
WWW.CDC.GOV/HIV/STATISTICS/BASICS/ATAGLANCE.HTML.  
ACCESSED OCTOBER 3, 2014.

**Some US 'hot spots' have HIV rates similar to those in sub-Saharan Africa**

African American women bear a disproportionate burden of the disease (TABLE 1).<sup>3</sup> In 2010, women accounted for an estimated 9,500 (20%) of the approximately 45,000 new infections occurring in the United States. Of these newly infected women, 64% were black, 18% were white, and 15% were Hispanic. Yet blacks make up only about 12% of the US population, whites make up 68%, and Hispanics 14%.

Regardless of race or ethnicity, unprotected heterosexual contact is the most common mode of transmission of HIV in women.<sup>2</sup>

Although the overall rates of HIV infection in the United States are relatively low, certain areas of the country have rates similar to those in sub-Saharan Africa, where most HIV-infected people reside.<sup>4</sup> The HIV Prevention Trials Network found that the incidence of HIV infection in US women living in these "hot spots," with high rates of poverty and HIV, was 0.32% per year. Compare this with the 2009 estimate of HIV incidence in the general population of US black women of similar age (0.05% per year) and the adult

incidence rates in Congo (0.28% per year) and Kenya (0.53% per year).<sup>5</sup> To better understand the epidemiology of HIV infection in women and concentrate our prevention efforts, we need to focus on these hot spots.

Misinformation abounds in these hot spots, as does disease. In a survey of residents of the South Side Chicago Housing Authority facilities,<sup>6</sup> many were aware that effective antiretroviral therapy existed, but one-fourth thought that there was an effective HIV vaccine, and 13% thought there was a cure.

In the early years, an HIV diagnosis was essentially a death sentence. Samji et al<sup>7</sup> estimated that life expectancy of patients who were prescribed antiretroviral therapy in the United States and Canada increased from 36.1 years in 2000–2002 to 51.4 years in 2006–2007, with the greatest increases in those who started with a baseline CD4 count above 350 cells/mm<sup>3</sup>. Now, a 20-year-old HIV-positive person with a CD4 count greater than 350 cells/mm<sup>3</sup> can expect to live into his or her early 70s.

But not all patients achieve these benefits. In 2009, despite major advances in diagnosis and treatment, HIV was the fourth leading cause of death among African American women ages 25 to 44, causing about 800 deaths, or 9% of all deaths in this group.<sup>8</sup>

**■ TEST ALL, UNLESS THEY OPT OUT**

Testing is vital in efforts to prevent and treat HIV infection. In 2006, the US Centers for Disease Control and Prevention (CDC) recommended that everyone between the ages of 13 and 64 be screened for HIV regardless of risk.<sup>9</sup>

The CDC recommends an opt-out strategy.<sup>9</sup> Rather than ask a patient whether he or she wants to be tested for HIV, the provider says something like, "I advise all of my patients to have an HIV test; as long as you have no objection, we will send you to the lab to have it done." This approach reduces barriers to HIV testing by eliminating pretest counseling and by making HIV testing routine and the standard of care. Separate consent is not required—clinicians just need to document whether the patient has accepted or declined the test.

Testing should be offered at least once and can be done in any health care setting, in-

cluding primary care offices and clinics, emergency rooms, health departments, and urgent care centers.<sup>9</sup> Patients at higher risk (injection drug users and their sex partners; people who exchange sex for money or drugs; sex partners of HIV-infected people; men who have sex with men; and heterosexuals who themselves or whose sex partners have had more than one sex partner since their most recent HIV test) should receive repeat screening annually.

HIV testing should also be offered to all pregnant women at entry into care and again in the third trimester. This strategy is cost-effective even in areas of low prevalence.<sup>9</sup> Since 2006, other professional organizations have made HIV testing recommendations as well (TABLE 2).<sup>9-12</sup>

A cost-effectiveness analysis suggested that routine opt-out testing is economically justified if the prevalence of HIV is greater than 0.2%.<sup>13</sup>

### ■ HIV-POSITIVE WOMEN NEED ROUTINE GYNECOLOGIC CARE

It is important for women with HIV to receive routine gynecologic care. Women with HIV have gynecologic problems similar to those of all women; however, they may be more vulnerable to certain conditions such as human papillomavirus (HPV) infection, which may be related to HIV disease or associated immunosuppression. In addition, pregnancy and family planning pose special challenges in this group.<sup>14</sup>

#### Cervical cancer screening

Effective screening and timely treatment of precancerous cervical lesions are key in preventing cervical cancer in women with or without HIV.

Persistent infection with HPV is necessary for the development of precancerous lesions as well as invasive cervical cancer. Most new cases of HPV infection in the general population resolve spontaneously within 2 years. However, in HIV-infected women, HPV infection is more likely to persist and progress to precancerous lesions of the cervix. This association is strongest in women with more compromised immune function as reflected by low CD4 cell counts and high viral loads.<sup>14</sup> Women with HIV have higher rates of infec-

TABLE 2

### Recommendations for HIV testing

#### US Centers for Disease Control and Prevention<sup>9</sup>

One-time screening for everyone between the ages of 13 and 64 (opt-out strategy, depending on state law)

#### American College of Obstetricians and Gynecologists<sup>10</sup>

Routine testing for women ages 19 to 64

Test women with risk factors outside of the age range (opt-out testing)

#### US Preventive Services Task Force<sup>11</sup>

Screen adolescents and adults, ages 15–65

#### Institute of Medicine<sup>12</sup>

Counsel and screen for HIV infection on an annual basis in sexually active women and men

tion with high-risk HPV strains and of cervical intraepithelial neoplasia compared with their HIV-negative counterparts.<sup>14</sup> The incidence of cervical cancer is five to six times higher in HIV-infected women in the United States than in the general population.<sup>15</sup>

According to guidelines from the Infectious Diseases Society of America,<sup>16</sup> the American College of Obstetricians and Gynecologists,<sup>10</sup> the CDC,<sup>17</sup> and the American Cancer Society,<sup>18</sup> all HIV-infected women should undergo cervical Papanicolaou (Pap) screening upon initiation into care, and this test should be repeated at 6 months and then annually if the results are normal. Patients with abnormalities on the Pap test should undergo colposcopy and, possibly, also biopsy. These abnormalities include atypical squamous cells of unknown significance and higher-grade lesions.<sup>16</sup>

Nearly one-fourth of HIV-positive women do not receive annual Pap smears despite engagement in care.<sup>19</sup> This is unacceptable, because half of the cases of cervical cancer diagnosed in the United States are in women who never received appropriate screening, and an additional 10% are in women who have not been screened in the previous 5 years.<sup>19</sup>

In HIV-infected women who have had a total hysterectomy, whether to continue Pap testing depends on their history before the surgery. Continued vaginal Pap smear screening is recommended after hysterectomy (including removal of the cervix) in HIV-infected women who have a history of cervical

**The CDC recommends HIV screening for everyone ages 13–64**

**TABLE 3**

**Recommendations for HIV treatment based on CD4 counts**

<b>Pretreatment CD4 count</b>	<b>Strength of recommendation</b>
< 350 cells/mm <sup>3</sup>	A I (strong recommendation based on evidence from randomized, controlled trials)
350–500 cells/mm <sup>3</sup>	A II (strong recommendation based on evidence from well-designed nonrandomized trials or observational cohort studies)
> 500 cells/mm <sup>3</sup>	B III (moderate-strength recommendation based on expert opinion)

BASED ON US DEPARTMENT OF HEALTH AND HUMAN SERVICES ADULT AND ADOLESCENT GUIDELINES.<sup>21</sup>

intraepithelial neoplasia grades 2 or 3 or invasive cancer.<sup>10,17,20</sup>

**■ TREATING HIV IN WOMEN: SPECIAL CONSIDERATIONS**

Because it is not yet possible to eradicate the HIV virus, the goals of antiretroviral therapy are to reduce HIV-associated morbidity and mortality, to restore and preserve immune function, to suppress viral load, and to prevent sexual and, in women, perinatal transmission of the virus.<sup>21</sup>

Antiretroviral therapy is recommended for all HIV-infected patients regardless of the CD4 count, although the strength of recommendation is weaker with higher CD4 counts (TABLE 3).<sup>21</sup> The recommendations for starting antiretroviral therapy and the goals of treatment are the same for men and women. TABLE 4 summarizes the recommendations for adolescents and adults who are new to treatment.<sup>21</sup> For women, additional factors that should be taken into account when considering a regimen include pregnancy potential and whether the drugs chosen for the regimen are considered safe in pregnancy.

Since the early years of the HIV epidemic, researchers have debated whether women attain the same benefits from antiretroviral therapy as men. US Food and Drug Administration investigators performed a meta-analysis of the efficacy outcomes in women in studies of antiretroviral drugs published between 2000 and 2008. They included randomized clinical trials reporting at least 48-week efficacy outcomes, with viral suppression defined as HIV RNA less than 50 copies/mL. The com-

bined database included 40 trials of 16 drugs from 7 drug classes with a total of 20,328 HIV-positive participants. Overall, there were no clinically or statistically significant differences between the sexes in 48-week efficacy outcomes or in rates of trial discontinuation due to adverse events, loss to follow-up, or death.<sup>22</sup>

Antiretroviral therapy may, however, cause different adverse effects in women than in men. For example:

**Nevirapine**, a nonnucleoside reverse transcriptase inhibitor, has been associated with the development of a rash and potentially life-threatening hepatotoxicity, more commonly in women than in men and at lower CD4 counts in women. This resulted in recommendations<sup>21</sup> to avoid starting a nevirapine-containing regimen in women with CD4 counts greater than 250 cells/mm<sup>3</sup> and in men with CD4 counts greater than 400 cells/mm<sup>3</sup>.

**Ritonavir** has been observed to cause a higher incidence of nausea and vomiting in women and a higher incidence of diarrhea in men. These are thought to be due to differences between men and women in weight and pharmacokinetics.<sup>23</sup>

**■ PRECONCEPTION COUNSELING FOR HIV-POSITIVE WOMEN**

Preconception counseling is an essential component of both primary and preventive care and should be considered the standard of care for all women of reproductive age who have HIV.<sup>24</sup> Health care providers who fully understand the impact of HIV infection and associated comorbidities upon a woman's reproductive health, fertility desires, and family

**In HIV-infected women, HPV infections are more likely to persist and progress to cervical cancer**

planning needs are better prepared to assist in their patients' reproductive health decisions.

The first few weeks of pregnancy are the most critical period in fetal development. During this time, a woman should be healthy and avoid any activities or substances that could cause adverse maternal or fetal outcomes. However, most patients present for prenatal care after this critical time period—thus the need for preconception counseling. Both the Infectious Diseases Society of America and the HIV Medicine Association recommend that all HIV-infected women of childbearing age be asked about their pregnancy plans and desires at the start of care and routinely thereafter.<sup>16</sup>

The goals of preconception care in women with HIV are to prevent unintended pregnancy, optimize maternal health before pregnancy, optimize pregnancy outcomes for mother and fetus, prevent perinatal HIV transmission, and prevent HIV transmission to an HIV-negative partner when trying to conceive.<sup>24</sup>

### Goal 1: Prevent unintended pregnancy

Nearly half of all pregnancies in the United States are unintended.<sup>25</sup> Moreover, the Women's Interagency HIV Study<sup>26</sup> showed that women with HIV are underusing effective contraception. In the Medical Monitoring Project, 85% of the women who had been pregnant since being diagnosed with HIV said that at least one pregnancy was unplanned.<sup>27</sup>

The consequences of unintended and unplanned pregnancies are serious and add significant burden to women, men, and families. Women who do not wish to become pregnant should be advised to use an effective method of contraception.

### Contraception

Contraception use varies worldwide. Factors affecting its use include the methods available, patient choice, current health conditions, religious beliefs, perception of method effectiveness, and side effects.<sup>24</sup>

The Women's Interagency HIV Study evaluated trends in contraception use from 1998 to 2010. Condoms were the most common form of contraception, and their use changed little over time. Fewer than 15% of women with HIV used no contraception. The use of long-acting reversible contraception,

TABLE 4

## Preferred antiretroviral agents for patients new to treatment

### RECOMMENDED REGIMEN REGARDLESS OF HIV RNA LEVEL OR CD4 COUNT

#### Nonnucleoside reverse transcriptase inhibitor-based regimen

Efavirenz/emtricitabine/tenofovir once daily

#### Protease inhibitor-based regimens

Atazanavir/ritonavir once daily + emtricitabine/tenofovir once daily

Darunavir/ritonavir once daily + emtricitabine/tenofovir once daily

#### Integrase inhibitor-based regimens

Raltegravir twice daily + emtricitabine/tenofovir once daily

Elvitegravir/cobicistat/tenofovir/emtricitabine once daily in patients with estimated creatinine clearance  $\geq$  70 mL/min

Dolutegravir once daily + abacavir/lamivudine once daily in patients who are HLA B\*5701-negative<sup>a</sup>

Dolutegravir once daily + tenofovir/emtricitabine once daily

### ADDITIONAL OPTIONS WHEN BASELINE HIV RNA IS LESS THAN 100,000 COPIES/mL

#### Nonnucleoside reverse transcriptase inhibitor-based regimens

Efavirenz once daily + abacavir/lamivudine once daily in patients who are HLA B\*5701-negative<sup>a</sup>

Rilpivirine/emtricitabine/tenofovir

#### Protease inhibitor-based regimen

Atazanavir/ritonavir once daily + abacavir/lamivudine once daily in patients who are HLA B\*5701-negative<sup>a</sup>

<sup>a</sup> Must be done before starting an abacavir-containing regimen to reduce the risk of hypersensitivity reaction, and it should be listed as an allergy in the patient's medical record.

FROM THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (DHHS) GUIDELINES.<sup>21</sup>

including injectable progestins, implants, and intrauterine devices, which minimize the need for user adherence, increased among HIV-negative women but not among HIV-positive women.<sup>28</sup>

The World Health Organization states that all available methods are safe for women with HIV except for spermicides with or without a diaphragm, as there is evidence linking the use of spermicides to an increased risk of HIV transmission (TABLE 5).<sup>29</sup>



**TABLE 5**

**World Health Organization recommendations on contraception in women with HIV or AIDS**

**No restriction**

- Condoms<sup>a</sup>
- Low-dose combined oral contraceptives<sup>b</sup>
- Combined estrogen-progestin patch
- Combined estrogen-progestin vaginal ring
- Combined injectable contraceptives
- Progestogen-only pills
- Depot medroxyprogesterone acetate
- Norethisterone enanthate
- Levonorgestrel and etonogestrel implants

**Advantages generally outweigh the theoretical or proven risks**

- Copper intrauterine devices (in HIV infection and continued use in AIDS)<sup>c</sup>
- Levonorgestrel intrauterine devices (in HIV infection and continued use in AIDS)

**Theoretical or proven risks usually outweigh the advantages**

- Copper intrauterine devices (initiation in AIDS)
- Levonorgestrel intrauterine devices (initiation in AIDS)
- Diaphragm<sup>d</sup>
- Spermicide<sup>d</sup>

**Acceptable under special circumstances**

- Female sterilization<sup>e</sup>

<sup>a</sup> Women with HIV or AIDS are advised to use condoms in addition to other methods of contraception to prevent transmission of HIV and other sexually transmitted diseases.

<sup>b</sup> There may be drug interactions between hormonal contraceptives and antiretroviral therapy.

<sup>c</sup> Intrauterine device users with AIDS should be closely monitored for pelvic infection.

<sup>d</sup> Spermicides and diaphragms may lead to increased viral shedding and HIV transmission to uninfected sexual partners through disruption of cervical mucosa.

<sup>e</sup> May require delay because of presence of an AIDS-related illness, and alternative temporary methods of contraception should be provided.

BASED ON WORLD HEALTH ORGANIZATION RECOMMENDATIONS.<sup>29</sup>

Some antiretroviral drugs may reduce the effectiveness of some contraceptives (TABLE 6); however, recommendations are based on pharmacokinetic studies, not on outcome studies. Condoms should be recommended not only to protect against pregnancy, but also to protect against sexually transmitted infections.

**Goal 2: Optimize maternal health before pregnancy**

Maternal health should be optimized before conceiving to reduce the risk of pregnancy-related morbidities and poor birth outcomes. This includes screening for other infections

and ensuring that other comorbidities, such as hypertension, diabetes, substance abuse, and mental illness, are well managed with medications that are safe to use in pregnancy (TABLE 7).

**Goal 3: Prevent perinatal HIV transmission**

Educating the patient about perinatal transmission is a fundamental component of pre-conception counseling. Topics that need to be addressed are transmission risk and methods to reduce the risk, including not breastfeeding after delivery.

**Goal 4: Prevent HIV transmission to an uninfected partner when trying to conceive**

HIV-discordant couples who desire pregnancy should receive appropriate counseling about methods to minimize risk of transmission to the uninfected partner while trying to conceive. There are a number of effective methods and techniques, which are beyond the scope of this review. Key components of all methods are to screen for and treat sexually transmitted infections in both partners and to use effective antiretroviral therapy and attain maximal viral suppression in the HIV-positive partner.

**Antiretroviral therapy for the HIV-infected partner** significantly reduced the risk of HIV transmission by 96% in the HIV Prevention Trials Network 052 trial.<sup>30</sup> Of note: this reduction was the result of both risk-reduction counseling and antiretroviral therapy. This was the first randomized clinical trial to demonstrate that antiretroviral therapy in those with some preserved immune function (CD4 counts 350–500 cells/mm<sup>3</sup>) in conjunction with risk-reduction counseling can reduce HIV transmission to an uninfected partner.

**Vaginal insemination without intercourse** is another option for female-positive couples. The man ejaculates into a condom without spermicide, and the contents are introduced with a non-needle syringe or turkey baster. This can be done at home and confers no risk to the uninfected male partner.<sup>31</sup> Chances of pregnancy can be maximized by insemination during the most fertile days of the menstrual cycle.

**Preexposure prophylaxis combined with timed intercourse.** In a study in Switzerland, the infected male partner was given antiretroviral therapy to suppress his viral load to less

TABLE 6

**Interactions between antiretroviral agents and hormonal contraceptives****Nonnucleoside reverse transcriptase inhibitors****Efavirenz**

Combined hormonal methods, progestin-only pills, and etonogestrel implants: use alternative or additional contraceptive method

**Nevirapine**

Combined hormonal methods, progestin-only pills, and etonogestrel implants: consider an alternative method or a reliable method of barrier contraception in addition to this method

**Ritonavir combined with a protease inhibitor (atazanavir, darunavir, lopinavir, saquinavir, or tipranavir)**

Combined hormonal methods and progestin-only pills: use alternative or additional contraceptive method  
Etonogestrel implants: consider an alternative method or a reliable method of barrier contraception in addition to this method

**Protease inhibitors without ritonavir****Atazanavir**

Combined hormonal methods: oral contraceptives should contain  $\leq 30 \mu\text{g}$  of ethinyl estradiol or use alternative method; those containing  $< 25 \mu\text{g}$  of ethinyl estradiol or progestins other than norethindrone or norgestimate have not been studied

**Fosamprenavir**

Combined hormonal contraceptives, etonogestrel implants: use alternative or additional contraceptive method  
Use of fosamprenavir alone with ethinyl estradiol/norethindrone may lead to loss of virologic response

**Nelfinavir**

Combined hormonal contraceptives, progestin-only pills, and etonogestrel implants: use alternative or additional contraceptive method

**Half of all US pregnancies are unintended, and 75% occur despite contraception**

than 50 copies/mL for at least 6 months, and luteinizing hormone was measured every day in the urine of the noninfected female partner. When the urinary luteinizing hormone level reached a peak, the woman received a dose of tenofovir in the morning, the couple had unprotected intercourse, and the woman took a second dose the next morning. In 53 cases, none of the female partners seroconverted for HIV.<sup>32</sup>

Health care providers need to document and update the relationship status, partner HIV status, and fertility desires of their HIV patients, both men and women, on a regular basis. Patient education should include awareness of referrals and options to help safely conceive when desired and achieve effective contraception when not.<sup>33</sup>

■ **WHEN HIV-POSITIVE WOMEN BECOME PREGNANT**

**Screening for HIV during pregnancy**

The CDC recommends prenatal screening for HIV in the first trimester or at entry into prenatal care. A repeat HIV test should be offered in the third trimester for women at risk of acquiring HIV, for women who have signs or symptoms of early HIV infection, in health care settings where prenatal testing yields at least 1 case of HIV infection per 1,000 women screened, and in areas of high HIV incidence. If women present to labor and delivery with unknown HIV status, rapid HIV testing should be done.<sup>9</sup>

If a woman acquires HIV during pregnancy, the infection may not be detected and may be transmitted to the infant at birth. From 2002 to 2006 in New York State, 3,396 HIV-

**TABLE 7**

**Preconception checklist for patients with HIV infection**

**Lifestyle**

Encourage regular moderate exercise  
Limit caffeine intake  
Screen for domestic violence

**Medical conditions**

Diabetes mellitus (optimize control)  
Hypertension  
Seizure disorders  
Deep venous thrombosis (avoid warfarin)  
Depression  
Anxiety

**Screen for infectious diseases**

Syphilis  
Hepatitis B, hepatitis C  
Rubella  
Gonorrhea  
Chlamydia  
Trichomoniasis

**Genetic**

Carrier screening (ethnic background): sickle cell anemia, thalassemia, Tay-Sachs disease  
Carrier screening (family history): cystic fibrosis

**Environmental toxins**

Initiate smoking cessation if appropriate  
Screen for alcohol use  
Screen for illicit drug use

**Other**

Prescribe a folic acid supplement

**Women with HIV > 1,000 copies/mL near term should undergo cesarean delivery**

exposed babies were born. Of these, 9 (22%) of 41 infants born to mothers who acquired HIV during pregnancy became infected, compared with 1.8% of those born to mothers who acquired HIV before pregnancy. Maternal acquisition of HIV during pregnancy was documented in only 1.3% of perinatal HIV exposures, but it was associated with 9 (13.8%) of the 65 perinatal transmission cases.<sup>34</sup>

Providers should be aware of the signs and symptoms of acute HIV infection and should have a low threshold for repeating HIV testing at any time during pregnancy. It has been estimated that 40% to 90% of patients with acute HIV infection experience fever, lymphadenopathy, pharyngitis, skin rash, myalgia, arthralgia, or other symptoms.<sup>35</sup> Providers often do

not recognize acute HIV infection, however, because the symptoms are similar to those of other common illnesses. Also, some individuals with the condition have no symptoms.

**Antiretroviral therapy during pregnancy**

In a landmark study, AIDS Clinical Trial Group 076 demonstrated that zidovudine monotherapy given during pregnancy, labor, and delivery and to the newborn reduced the risk of HIV transmission to the infant by 67%, from 25% to 8%.<sup>36</sup> Other studies demonstrated that combination therapy further decreased the risk of HIV transmission to 1% to 2%.<sup>37</sup>

The US Department of Health and Human Services recommends that all HIV-positive women who are pregnant receive effective combination antiretroviral therapy regardless of CD4 count to minimize the risk of mother-to-child transmission.<sup>37</sup>

The goals of HIV treatment during pregnancy are to maintain the woman's health, restore her immune system, suppress viral replication, and decrease the risk of perinatal transmission. The preferred antiretroviral therapy for pregnant women differs from that for nonpregnant women and is based on evolving experience and information about safety, efficacy, and tolerability in pregnancy (TABLE 8). A woman who presents for prenatal care on a suppressive regimen should continue that regimen as long as she can tolerate it because there is a risk of losing virologic control when switching regimens, and this may increase the risk of perinatal transmission.<sup>37</sup>

Physiologic changes that occur during pregnancy may alter drug disposition, which could potentially lead to decreased drug exposure. Some of the changes include an increase in total body water, decreased protein binding, induction of hepatic metabolic pathways, and increased clearance of drugs eliminated by the kidneys.<sup>38</sup> These changes may be associated with incomplete virologic suppression, virologic failure, or development of drug resistance, so altered doses of some antiretroviral drugs or careful monitoring of viral load should be considered, particularly in the second and third trimester.

**Delivery**

Women who have a viral load greater than 1,000 copies/mL near the end of pregnancy



TABLE 8

**Recommendations for use of antiretroviral drugs in pregnant women**

Drugs	Comments
<b>Preferred two-nucleoside reverse transcriptase inhibitor (NRTI) backbone</b>	
Abacavir/lamivudine	Available as fixed-drug combination, can be administered once daily, but hypersensitivity reactions are possible. Abacavir should not be used in patients who test positive for HLA-B*5701.
Tenofovir/emtricitabine or lamivudine	Tenofovir/emtricitabine is available as a fixed-drug combination. Either tenofovir/emtricitabine or tenofovir/lamivudine can be administered once daily. Tenofovir has potential renal toxicity; thus, tenofovir-based dual NRTI combinations should be used with caution in patients with renal insufficiency.
Zidovudine/lamivudine	Available as fixed-drug combination. Nucleoside reverse transcriptase inhibitor combination with most experience for use in pregnancy but has disadvantages of requirement for twice-daily administration and increased potential for hematologic toxicity.
<b>Protease inhibitor regimens</b>	
Atazanavir/ritonavir + a preferred two-NRTI backbone	Once-daily administration.
Lopinavir/ritonavir + a preferred two-NRTI backbone	Twice-daily administration. Once-daily lopinavir/ritonavir is not recommended for pregnant women.
<b>Nonnucleoside reverse transcriptase inhibitor regimen</b>	
Efavirenz + a preferred two-NRTI backbone <sup>a</sup>	Concern because of birth defects seen in primate study; risk in humans is unclear. Postpartum contraception must be ensured. Preferred regimen in women requiring co-administration of drugs with significant interactions with protease inhibitors.
<b>Alternative regimens</b>	
Darunavir/ritonavir + a preferred two-NRTI backbone	Less experience with use in pregnancy than atazanavir/ritonavir and lopinavir/ritonavir.
Saquinavir/ritonavir + a preferred two-NRTI backbone	Baseline electrocardiogram is recommended before initiation of saquinavir/ritonavir because of potential PR and QT prolongation; contraindicated with pre-existing cardiac conduction system disease. Large pill burden.
<b>Nonnucleoside reverse transcriptase inhibitor regimen</b>	
Nevirapine + a preferred two-NRTI backbone	Nevirapine should be used with caution when initiating antiretroviral therapy in women with CD4 cell counts > 250 cells/mm <sup>3</sup> . Use nevirapine and abacavir together with caution; both can cause hypersensitivity reactions within the first few weeks after initiation.
<b>Integrase inhibitor regimen</b>	
Raltegravir + a preferred two-NRTI backbone	Limited data on raltegravir in pregnancy, but may be considered when drug interactions with protease inhibitor regimens are a concern.
<b>Insufficient data in pregnancy to recommend routine use in women new to antiretroviral therapy<sup>b</sup></b>	
Dolutegravir, elvitegravir/cobicistat/tenofovir/emtricitabine fixed-drug combination, fosamprenavir/ritonavir, maraviroc, rilpivirine	
<b>Not recommended<sup>c</sup></b>	
Abacavir/lamivudine/zidovudine, stavudine, didanosine, indinavir/ritonavir, nelfinavir, ritonavir, etravirine, enfuvirtide, tipranavir	

<sup>a</sup> May be initiated after the first 8 weeks of pregnancy.<sup>b</sup> Drugs that are approved for use in adults but lack adequate pregnancy-specific pharmacokinetic or safety data.<sup>c</sup> Drugs whose use is not recommended because of toxicity, lower rate of viral suppression, or because not recommended in patients new to antiretroviral therapy.ADAPTED FROM PANEL ON TREATMENT OF HIV-INFECTED PREGNANT WOMEN AND PREVENTION OF PERINATAL TRANSMISSION. RECOMMENDATIONS FOR USE OF ANTIRETROVIRAL DRUGS IN PREGNANT HIV-1-INFECTED WOMEN FOR MATERNAL HEALTH AND INTERVENTIONS TO REDUCE PERINATAL HIV TRANSMISSION IN THE UNITED STATES. MARCH 28, 2014. [HTTP://AIDSINFO.NIH.GOV/CONTENTFILES/PERINATALGL.PDF](http://aidsinfo.nih.gov/contentfiles/perinatalgl.pdf). ACCESSED OCTOBER 3, 2014.

should undergo a cesarean delivery at 38 weeks and, before surgery, should receive intravenous zidovudine to reduce the risk of perinatal transmission. For women with viral loads below the threshold of 1,000 copies/mL, there is no proven added benefit to cesarean delivery, and in this situation it should be performed only for standard obstetric indications. Antiretroviral regimens should be continued during labor.<sup>37</sup>

**HIV IN OLDER ADULTS**

By 2015, approximately 50% of people with HIV will be over age 50.<sup>39</sup> Unfortunately, older people and their providers often underestimate their risk of acquiring HIV. Many older people are newly single and may engage in sexual activity with new partners. Also, older people may be reluctant to use condoms as the need for contraception is past.<sup>40,41</sup>

Baseline HIV RNA levels tend to be higher and CD4 cell counts lower in patients

diagnosed with HIV at older ages. These observations support previous ones that older HIV-infected patients may have advanced HIV disease at the time of diagnosis, perhaps in part due to delayed testing.<sup>42</sup> Other possible factors are limited income, comorbid illness, polypharmacy, and insufficient data on drug interactions in the elderly.<sup>41,42</sup>

A prompt diagnosis is important for older patients because HIV may accelerate aging, and aging may speed up HIV progression. Studies have shown that aging is associated with more rapid progression to AIDS, particularly among people who are older than 40 at seroconversion.<sup>43</sup> Other studies have reported that older patients have better virologic responses to antiretroviral therapy but have a blunted immune response, more AIDS-defining events, and a higher mortality rate than younger patients.<sup>42</sup>

**REFERENCES**

1. **Centers for Disease Control and Prevention (CDC).** Immunodeficiency among female sexual partners of males with acquired immune deficiency syndrome (AIDS) - New York. *MMWR Morb Mortal Wkly Rep* 1983; 31:697-698.
2. **Centers for Disease Control and Prevention (CDC).** Estimated HIV incidence in the United States, 2007-2010. *HIV Surveillance Supplemental Report* 2012;17(No. 4). [www.cdc.gov/hiv/topics/surveillance/resources/reports/#supplemental](http://www.cdc.gov/hiv/topics/surveillance/resources/reports/#supplemental). Accessed October 3, 2014.
3. **Centers for Disease Control and Prevention.** HIV in the United States: at a glance. [www.cdc.gov/hiv/statistics/basics/ata glance.html](http://www.cdc.gov/hiv/statistics/basics/ata glance.html). Accessed October 3, 2014.
4. **El-Sadr WM, Mayer KH, Hodder SL.** AIDS in America—forgotten but not gone. *N Engl J Med* 2010; 362:967-970.
5. **Eshleman SH, Hughes JP, Laeyendecker O, et al.** Use of a multifaceted approach to analyze HIV incidence in a cohort study of women in the United States: HIV Prevention Trials Network 064 Study. *J Infect Dis* 2013; 207:223-231.
6. **Djokic D, Englund J, Daum R, et al.** HIV knowledge and attitudes toward HIV testing of South Side Chicago Housing Authority residents. *AIDS Patient Care STDS* 2009; 23:23-28.
7. **Samji H, Cescon A, Hogg RS, et al; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA.** Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. *PLoS One* 2013; 8:e81355.
8. **Centers for Disease Control and Prevention (CDC).** HIV/AIDS. HIV mortality (through 2010). [www.cdc.gov/hiv/library/slideSets/index.html](http://www.cdc.gov/hiv/library/slideSets/index.html). Accessed October 3, 2014.
9. **Branson BM, Handsfield HH, Lampe MA, et al; Centers for Disease Control and Prevention (CDC).** Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. *MMWR Recomm Rep* 2006; 55:1-17.
10. **The American College of Obstetricians and Gynecologists (ACOG).** Routine Human Immunodeficiency Virus Screening. Committee Opinion Number 596, May 2014. (Replaces Committee Opinion Number 411, August 2008.) [www.acog.org/Resources\\_And\\_Publications/Committee\\_Opinions/Committee\\_on\\_Gynecologic\\_Practice/Routine\\_Human\\_Immunodeficiency\\_Virus\\_Screening](http://www.acog.org/Resources_And_Publications/Committee_Opinions/Committee_on_Gynecologic_Practice/Routine_Human_Immunodeficiency_Virus_Screening). Accessed October 3, 2014.
11. **US Preventive Services Task Force.** Screening for HIV. <http://www.uspreventiveservicestaskforce.org/Page/Topic/recommendation-summary/human-immunodeficiency-virus-hiv-infection-screening>. Accessed October 3, 2014.
12. **Institute of Medicine.** HIV screening and access to care health care system capacity for increased HIV testing and provision of care. [www.iom.edu/Reports/2011/HIV-Screening-and-Access-to-Care-Health-Care-System-Capacity-for-Increased-HIV-Testing-and-Provision-of-Care.aspx](http://www.iom.edu/Reports/2011/HIV-Screening-and-Access-to-Care-Health-Care-System-Capacity-for-Increased-HIV-Testing-and-Provision-of-Care.aspx). Accessed October 3, 2014.
13. **Walensky RP, Freedberg KA, Weinstein MC, Paltiel AD.** Cost-effectiveness of HIV testing and treatment in the United States. *Clin Infect Dis* 2007; 45(suppl 4):S248-S254.
14. **ACOG Committee on Practice Bulletins—Gynecology.** ACOG Practice Bulletin No. 117: Gynecologic care for women with human immunodeficiency virus. *Obstet Gynecol* 2010; 116:1492-1509.
15. **Centers for Disease Control and Prevention (CDC).** Invasive cancer incidence—United States, 2009. *MMWR Morb Mortal Wkly Rep* 2013; 62:113-118.
16. **Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA.** Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. *Clin Infect Dis* 2014; 58:e1-e34.
17. **Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents.** Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. [http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult\\_oi.pdf](http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf). Accessed October 3, 2014.
18. **Saslow D, Solomon D, Lawson HW, et al; ACS-ASCCP-ASCP Cervical Cancer Guideline Committee.** American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. *CA Cancer J Clin* 2012; 62:147-172.
19. **Oster AM, Sullivan PS, Blair JM.** Prevalence of cervical cancer screening of HIV-infected women in the United States. *J Acquir Immune Defic Syndr* 2009; 51:430-436.
20. **Paramsothy P, Duerr A, Heilig CM, et al; HIV Epidemiology Research (HER) Study Group.** Abnormal vaginal cytology in HIV-infected and at-risk women after hysterectomy. *J Acquir Immune Defic Syndr* 2004; 35:484-491.

21. **Panel on Antiretroviral Guidelines for Adults and Adolescents.** Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. <http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf>. Accessed October 3, 2014.
22. **Soon GG, Min M, Struble KA, et al.** Meta-analysis of gender differences in efficacy outcomes for HIV-positive subjects in randomized controlled clinical trials of antiretroviral therapy (2000–2008). *AIDS Patient Care STDS* 2012; 26:444–453.
23. **Clark RA, Squires KE.** Gender-specific considerations in the antiretroviral management of HIV-infected women. *Expert Rev Anti Infect Ther* 2005; 3:213–227.
24. **Johnson K, Posner SF, Biermann J, et al; CDC/ATSDR Preconception Care Work Group; Select Panel on Preconception Care.** Recommendations to improve preconception health and health care—United States. A report of the CDC/ATSDR Preconception Care Work Group and the Select Panel on Preconception Care. *MMWR Recomm Rep* 2006; 55:1–23.
25. **Finer LB, Zolna MR.** Unintended pregnancy in the United States: incidence and disparities, 2006. *Contraception* 2011; 84:478–485.
26. **Massad LS, Evans CT, Wilson TE, et al.** Contraceptive use among US women with HIV. *J Womens Health (Larchmt)* 2007; 16:657–666.
27. **Sutton MY, Patel R, Frazier EL.** Unplanned pregnancies among HIV-infected women in care—United States. *J Acquir Immune Defic Syndr* 2014; 65:350–358.
28. **Sun M, Peipert JF, Zhao Q, et al.** Trends in contraceptive use among women with human immunodeficiency virus. *Obstet Gynecol* 2012; 120:783–790.
29. **World Health Organization (WHO).** Medical eligibility criteria for contraceptive use. 4th ed. [http://whqlibdoc.who.int/publications/2010/9789241563888\\_eng.pdf](http://whqlibdoc.who.int/publications/2010/9789241563888_eng.pdf). Accessed October 3, 2014.
30. **Cohen MS, Chen YQ, McCauley M, et al; HPTN 052 Study Team.** Prevention of HIV-1 infection with early antiretroviral therapy. *N Engl J Med* 2011; 365:493–505.
31. **Mmeje O, Cohen CR, Cohan D.** Evaluating safer conception options for HIV-serodiscordant couples (HIV-infected female/HIV-uninfected male): a closer look at vaginal insemination. *Infect Dis Obstet Gynecol* 2012; 2012:587–651.
32. **Vernazza PL, Graf I, Sonnenberg-Schwan U, Geit M, Meurer A.** Preexposure prophylaxis and timed intercourse for HIV-discordant couples willing to conceive a child. *AIDS* 2011; 25:2005–2008.
33. **Lampe MA, Smith DK, Anderson GJ, Edwards AE, Nesheim SR.** Achieving safe conception in HIV-discordant couples: the potential role of oral preexposure prophylaxis (PrEP) in the United States. *Am J Obstet Gynecol* 2011; 204:488.e1–e8.
34. **Birkhead GS, Pulver WP, Warren BL, Hackel S, Rodríguez D, Smith L.** Acquiring human immunodeficiency virus during pregnancy and mother-to-child transmission in New York: 2002–2006. *Obstet Gynecol* 2010; 115:1247–1255.
35. **Yerly S, Hirschel B.** Diagnosing acute HIV infection. *Expert Rev Anti Infect Ther* 2012; 10:31–41.
36. **Connor EM, Sperling RS, Gelber R, et al.** Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. *Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.* *N Engl J Med* 1994; 331:1173–1180.
37. **Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission.** Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. <http://aidsinfo.nih.gov/contentfiles/vguidelines/PerinatalGL.pdf>. Accessed October 3, 2014.
38. **Mirochnick M, Capparelli E.** Pharmacokinetics of antiretrovirals in pregnant women. *Clin Pharmacokinet* 2004; 43:1071–1087.
39. **Smith G; Senate Committee on Aging.** HIV over fifty: exploring the new threat. Washington, DC; 2005. <http://www.aging.senate.gov/imo/media/doc/5122005.pdf>. Accessed October 3, 2014.
40. **Illa L, Brickman A, Saint-Jean G, et al.** Sexual risk behaviors in late middle age and older HIV seropositive adults. *AIDS Behav* 2008; 12:935–942.
41. **Luther VP, Wilkin AM.** HIV infection in older adults. *Clin Geriatr Med* 2007; 23:567–583.
42. **Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group; Sabin CA, Smith CJ, d’Arminio Monforte A, et al.** Response to combination antiretroviral therapy: variation by age. *AIDS* 2008; 22:1463–1473.
43. **Pezzotti P, Phillips AN, Dorrucchi M, et al.** Category of exposure to HIV and age in the progression to AIDS: longitudinal study of 1,199 people with known dates of seroconversion. *HIV Italian Seroconversion Study Group.* *BMJ* 1996; 313:583–586.

ADDRESS: William R. Short, MD, MPH, Division of Infectious Diseases, Jefferson Medical College of Thomas Jefferson University, 1015 Chestnut Street, Suite 1020, Philadelphia, PA 19107; e-mail: [william.short@jefferson.edu](mailto:william.short@jefferson.edu)



The *Cleveland Clinic Journal of Medicine* uses the AMA's database of physician names and addresses. (All physicians are included in the AMA database, not just members of the AMA.) Only the AMA can update this data, and the AMA will accept a change-of-address notice only from you.

Be sure your primary specialty and type of practice also are up-to-date on AMA records. This information is important in determining who receives the *Cleveland Clinic Journal of Medicine*.

If you have ever notified the AMA that you did not want to receive mail, you will not receive the *Cleveland Clinic Journal of Medicine*. You can reverse that directive by notifying the AMA. Please note that a change of address with the AMA will redirect all medically related mailings to the new location.

**FOR FASTER SERVICE**

- PHONE 800-262-3211 ext. 5192
- FAX 312-464-5843
- E-MAIL [nicole.neal@www.ama-assn.org](mailto:nicole.neal@www.ama-assn.org)

or send a recent mailing label along with new information to:

AMA  
DEPARTMENT OF DATA SERVICES  
515 North State Street  
Chicago, IL 60654

**NEW INFORMATION**

NAME \_\_\_\_\_

STREET ADDRESS \_\_\_\_\_

CITY \_\_\_\_\_

STATE \_\_\_\_\_ ZIP \_\_\_\_\_

Please allow 6 to 8 weeks for change to take effect